FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016111743> ?p ?o ?g. }

• W2016111743 endingPage "2063.e3" @default.
• W2016111743 startingPage "2047" @default.
• W2016111743 abstract "New antiviral agents with activity against hepatitis C virus (HCV) are needed to optimize treatment for chronic hepatitis C (CHC). We evaluated the pharmacokinetics of setrobuvir (a non-nucleoside HCV polymerase inhibitor) in healthy volunteers (study 1 & 2) and its antiviral efficacy in patients with genotype 1, noncirrhotic treatment-naive CHC (study 3).Three studies investigated the pharmacokinetics and pharmacodynamics of setrobuvir. First, sequential cohorts of volunteers were randomly assigned to receive single oral doses of setrobuvir 400 to 3000 mg or placebo in a double-blind, ascending dose study. In the second study, volunteers were randomly assigned to receive multiple doses of setrobuvir (400 or 800 mg once daily [QD] or 600 mg twice a day [BID]). In the third study, patients with genotype 1 CHC received setrobuvir (200, 400, or 800 mg) or placebo BID for 3 days.After single doses of setrobuvir (400-3000 mg) to volunteers in a fasted state, peak Cmax and AUC0-∞ increased in a less than dose-proportional manner. The mean apparent t½z ranged from 22.0 to 31.3 hours and was not dose related. Cmax and AUC increased significantly (4.3- and 6.3-fold, respectively) in volunteers who received 2000 mg with a high-fat meal versus fasting. After multiple oral doses, steady state was achieved after 7 days of dosing (400 or 800 mg QD and 600 mg BID) and accumulation was dose-independent. Mean day 14 plasma exposure increased in a less than dose-proportional manner in volunteers who received 400 and 800 mg QD, but it was more than dose-proportional in volunteers receiving 600 mg BID. Dose did not affect the mean t½z (range, 24.1-26.6 hours), apparent oral clearance (0.254-0.516 L/h), or apparent volume of distribution (9.60-18.1 L). In patients with CHC, dose-related reductions in HCV RNA concentration were apparent within 24 hours of the start of treatment. Reductions from baseline to the end of treatment (day 3) in patients treated with setrobuvir 200, 400, and 800 mg BID were -2.1, -2.2, and -2.9 log10 IU/mL, respectively (vs ≤0.1 log10 IU/mL with placebo). Reductions in HCV RNA were greater in patients with genotype 1b (range, -2.7 to -3.1 log10 IU/mL) than in patients with genotype 1a (range, -1.3 to -2.7 log10 IU/mL). Setrobuvir was well tolerated, with no serious adverse events.The steady state pharmacokinetics of setrobuvir appear to be dose proportional, and setrobuvir produces a mean reduction of 2.9 log10 IU/mL in HCV RNA over 3 days in patients with genotype 1 (a and b) treated with 800 mg BID. ClinicalTrials.gov identifier: NCT00782353." @default.
• W2016111743 created "2016-06-24" @default.
• W2016111743 creator A5005865510 @default.
• W2016111743 creator A5012385241 @default.
• W2016111743 creator A5012723273 @default.
• W2016111743 creator A5030901855 @default.
• W2016111743 creator A5050449339 @default.
• W2016111743 creator A5085872163 @default.
• W2016111743 date "2014-12-01" @default.
• W2016111743 modified "2023-10-01" @default.
• W2016111743 title "Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor" @default.
• W2016111743 cites W1972821220 @default.
• W2016111743 cites W1973675889 @default.
• W2016111743 cites W2024571876 @default.
• W2016111743 cites W2028628438 @default.
• W2016111743 cites W2030407595 @default.
• W2016111743 cites W2042158802 @default.
• W2016111743 cites W2046658390 @default.
• W2016111743 cites W2052005188 @default.
• W2016111743 cites W2066449293 @default.
• W2016111743 cites W2078251659 @default.
• W2016111743 cites W2078991404 @default.
• W2016111743 cites W2107512529 @default.
• W2016111743 cites W2113428683 @default.
• W2016111743 cites W2113864802 @default.
• W2016111743 cites W2120733999 @default.
• W2016111743 cites W2125963799 @default.
• W2016111743 cites W2127189337 @default.
• W2016111743 cites W2141214317 @default.
• W2016111743 cites W2143244227 @default.
• W2016111743 cites W2143559032 @default.
• W2016111743 cites W2148840656 @default.
• W2016111743 cites W2149786401 @default.
• W2016111743 cites W2150652264 @default.
• W2016111743 cites W2157961528 @default.
• W2016111743 cites W2164466220 @default.
• W2016111743 cites W4211077792 @default.
• W2016111743 doi "https://doi.org/10.1016/j.clinthera.2014.10.002" @default.
• W2016111743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25456558" @default.
• W2016111743 hasPublicationYear "2014" @default.
• W2016111743 type Work @default.
• W2016111743 sameAs 2016111743 @default.
• W2016111743 citedByCount "10" @default.
• W2016111743 countsByYear W20161117432015 @default.
• W2016111743 countsByYear W20161117432017 @default.
• W2016111743 countsByYear W20161117432018 @default.
• W2016111743 countsByYear W20161117432019 @default.
• W2016111743 countsByYear W20161117432020 @default.
• W2016111743 countsByYear W20161117432021 @default.
• W2016111743 countsByYear W20161117432022 @default.
• W2016111743 crossrefType "journal-article" @default.
• W2016111743 hasAuthorship W2016111743A5005865510 @default.
• W2016111743 hasAuthorship W2016111743A5012385241 @default.
• W2016111743 hasAuthorship W2016111743A5012723273 @default.
• W2016111743 hasAuthorship W2016111743A5030901855 @default.
• W2016111743 hasAuthorship W2016111743A5050449339 @default.
• W2016111743 hasAuthorship W2016111743A5085872163 @default.
• W2016111743 hasConcept C111113717 @default.
• W2016111743 hasConcept C112705442 @default.
• W2016111743 hasConcept C126322002 @default.
• W2016111743 hasConcept C142724271 @default.
• W2016111743 hasConcept C203014093 @default.
• W2016111743 hasConcept C204787440 @default.
• W2016111743 hasConcept C22979827 @default.
• W2016111743 hasConcept C2522874641 @default.
• W2016111743 hasConcept C27081682 @default.
• W2016111743 hasConcept C2776408679 @default.
• W2016111743 hasConcept C2776455275 @default.
• W2016111743 hasConcept C2777056448 @default.
• W2016111743 hasConcept C2777288759 @default.
• W2016111743 hasConcept C71924100 @default.
• W2016111743 hasConcept C90924648 @default.
• W2016111743 hasConcept C98274493 @default.
• W2016111743 hasConceptScore W2016111743C111113717 @default.
• W2016111743 hasConceptScore W2016111743C112705442 @default.
• W2016111743 hasConceptScore W2016111743C126322002 @default.
• W2016111743 hasConceptScore W2016111743C142724271 @default.
• W2016111743 hasConceptScore W2016111743C203014093 @default.
• W2016111743 hasConceptScore W2016111743C204787440 @default.
• W2016111743 hasConceptScore W2016111743C22979827 @default.
• W2016111743 hasConceptScore W2016111743C2522874641 @default.
• W2016111743 hasConceptScore W2016111743C27081682 @default.
• W2016111743 hasConceptScore W2016111743C2776408679 @default.
• W2016111743 hasConceptScore W2016111743C2776455275 @default.
• W2016111743 hasConceptScore W2016111743C2777056448 @default.
• W2016111743 hasConceptScore W2016111743C2777288759 @default.
• W2016111743 hasConceptScore W2016111743C71924100 @default.
• W2016111743 hasConceptScore W2016111743C90924648 @default.
• W2016111743 hasConceptScore W2016111743C98274493 @default.
• W2016111743 hasIssue "12" @default.
• W2016111743 hasLocation W20161117431 @default.
• W2016111743 hasLocation W20161117432 @default.
• W2016111743 hasOpenAccess W2016111743 @default.
• W2016111743 hasPrimaryLocation W20161117431 @default.
• W2016111743 hasRelatedWork W1573667742 @default.
• W2016111743 hasRelatedWork W1982777678 @default.
• W2016111743 hasRelatedWork W1997101420 @default.
• W2016111743 hasRelatedWork W2004325424 @default.

• next